Figure 3.

Ginsenoside Rg1 alleviates liver inflammation in NAFLD models. (A, B) Ginsenoside Rg1 attenuates the pathologic change of liver tissues in the NAFLD model in a dose- and time-dependent manner. The sections of liver tissues were detected by HE after ginsenoside Rg1 treatment for 4 or 8 weeks. (C, D) Ginsenoside Rg1 inhibits the secretion of inflammatory cytokines in the NAFLD model in a dose- and time-dependent manner. Serum concentrations of IL-6, IL-1β, and TNFα were detected by enzyme-linked immunosorbent assay (ELISA) kits after ginsenoside Rg1 treatment for 4 or 8 weeks. The values shown are mean ± SEM of the data from three independent experiments. ^#Significant compared with the control group alone, P < 0.05; *significant compared with the model group alone, P < 0.05; ^@significant compared with simvastatin alone, P < 0.05.